Last updated on December 2019

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer


Brief description of study

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of major pathological response.

Clinical Study Identifier: NCT03800134

Find a site near you

Start Over

Research Site

Toyoake-shi, Japan
8.84miles
  Connect »